MDCX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.270

Open

1.190

VWAP

1.00

Vol

161.00K

Mkt Cap

31.00M

Low

1.190

Amount

196.00K

EV/EBITDA(TTM)

--

Total Shares

25.00M

EV

28.00M

EV/OCF(TTM)

--

P/S(TTM)

--

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Show More

Events Timeline

(ET)

2026-01-22

07:40:00

Medicus Pharma Subsidiary Antev Amends License Agreement with LifeArc

2026-01-12 (ET)

2026-01-12

07:50:00

Medicus Pharma Teverelix Clinical Data Accepted for AACE Meeting

2025-12-22 (ET)

2025-12-22

07:50:00

Medicus Pharma Partners with Reliant AI to Develop AI-Powered Data Analytics Platform

2025-12-15 (ET)

2025-12-15

07:50:00

Medicus Pharma Completes Enrollment of 90 Patients in Phase 2 Study of Doxorubicin Microneedle Array

2025-12-01 (ET)

2025-12-01

07:40:00

Medicus Pharma Appoints Carolyn Bonner as CFO Effective Immediately

2025-11-24 (ET)

2025-11-24

08:13:59

Medicus Pharma Investigates New Treatment Innovations for Prostate and Skin Cancers

2025-11-19 (ET)

2025-11-19

17:05:09

Medicus Pharma Seeks Approval to Sell 2.68 Million Common Shares for Shareholders

2025-11-17 (ET)

2025-11-17

07:33:53

Medicus Pharma Files CNPV Application for SKNJCT-003

2025-11-13 (ET)

2025-11-13

07:54:51

Medicus Pharma Secures Complete UK Regulatory Approval to Broaden Phase 2 Study

2025-10-29 (ET)

2025-10-29

07:39:41

Medicus Pharma Forms Strategic Partnership with Gorlin Syndrome Alliance

News

an image of Globenewswire

01-20Globenewswire

Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary

an image of Newsfilter

01-20Newsfilter

Medicus Pharma Rings Nasdaq Opening Bell to Celebrate One-Year Listing Anniversary

an image of Globenewswire

01-12Globenewswire

Medicus Pharma (NASDAQ: MDCX) Announces Teverelix Clinical Data Accepted for AACE 2026 Presentation

an image of NASDAQ.COM

2025-12-01NASDAQ.COM

Medicus Pharma Names Carolyn Bonner as CFO and President

an image of SeekingAlpha

2025-12-01SeekingAlpha

Medicus Pharma names new Chief Financial Officer

an image of Benzinga

2025-10-29Benzinga

D. Boral Capital Reiterates Buy Rating for Medicus Pharma with $27 Price Target

1 Analyst Rating

Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Brookline

Buy

upgrade

$12 -> $20

AI Analysis

2025-09-24

Reason

Brookline

Price Target

$12 -> $20

AI Analysis

2025-09-24

upgrade

Buy

Reason

Brookline raised the firm's price target on Medicus Pharma to $20 from $12 and keeps a Buy rating on the shares. The firm is updating its model following completion of aquisition of Antev Limited. Medicus acquired 98.6% of Antev for $75M, which includes $2.97M in cash and 1,603,164 common shares of Medicus, plus $65M in contingent payments tied to potential future Teverelix Phase 2 trial data and New Drug Application approvals. Brookline is including the potential of Teverelix in Acute Urinary Retention in its model, but does not include the potential for Teverelix in prostate cancer in its model and expects to add it to the model following Phase 2 data.

D. Boral Capital

Jason Kolbert

Buy

maintain

$14 -> $27

2025-05-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14 -> $27

2025-05-12

maintain

Buy

Reason

D. Boral Capital analyst Jason Kolbert raised the firm's price target on Medicus Pharma to $27 from $14 and keeps a Buy rating on the shares after the company signed a binding letter of intent to acquire Antev. This acquisition adds "significant strategic value" by bringing in Teverelix, a next-generation GnRH antagonist with strong clinical rationale and late-stage readiness, the analyst tells investors in a research note. The firm says Teverelix addresses two large, underserved markets - acute urinary retention recurrence prevention and advanced prostate cancer in patients with high cardiovascular risk. D. Boral views the transaction as a "savvy, de-risked pipeline expansion that materially enhances Medicus' near-commercial portfolio and positions the company for accelerated value creation."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MDCX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Medicus Pharma Ltd (MDCX.O) is -0.96, compared to its 5-year average forward P/E of -1.72. For a more detailed relative valuation and DCF analysis to assess Medicus Pharma Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-1.72

Current PE

-0.96

Overvalued PE

-0.73

Undervalued PE

-2.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding MDCX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Medicus Pharma Ltd (MDCX) stock price today?

The current price of MDCX is 1.19 USD — it has decreased -4.8 % in the last trading day.

What is Medicus Pharma Ltd (MDCX)'s business?

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

What is the price predicton of MDCX Stock?

Wall Street analysts forecast MDCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDCX is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Medicus Pharma Ltd (MDCX)'s revenue for the last quarter?

Medicus Pharma Ltd revenue for the last quarter amounts to -7.00M USD, increased 187.41 % YoY.

What is Medicus Pharma Ltd (MDCX)'s earnings per share (EPS) for the last quarter?

Medicus Pharma Ltd. EPS for the last quarter amounts to -6757829.00 USD, decreased % YoY.

How many employees does Medicus Pharma Ltd (MDCX). have?

Medicus Pharma Ltd (MDCX) has 12 emplpoyees as of January 31 2026.

What is Medicus Pharma Ltd (MDCX) market cap?

Today MDCX has the market capitalization of 31.00M USD.